Introduction {#s1}
============

As the largest and most diverse group of membrane receptors in eukaryotes, GPCRs mediate a wide variety of physiological functions ([@bib93]; [@bib149]; [@bib75]; [@bib181]; [@bib76]), including vision, olfaction, taste, neurotransmission, endocrine and immune responses via more than 800 family members, and are involved in many diseases ([@bib142]; [@bib160]; [@bib180]; [@bib174]; [@bib52]). Therefore, GPCRs are important drug targets. There are 475 marketed drugs (\~34% of all FDA-approved therapeutic agent agents) targeting 108 members of the GPCR superfamily ([@bib52]; [@bib51]; [@bib3]). Class A is the largest and most diverse GPCR subfamily in humans ([@bib83]; [@bib8]; [@bib40]; [@bib64]), including 388 olfactory ([@bib86]; [@bib164]) and 286 non-olfactory receptors ([@bib136]; [@bib124]) ([Figure 1a](#fig1){ref-type="fig"}). They share a seven-transmembrane (7TM) helices domain, with ligand binding pocket and G-protein-binding region located in the extracellular and intracellular ends of the helix bundle. Responding to a wide variety of extracellular signals ranged from small molecules to peptides even proteins, the extracellular facing ligand-binding pockets have evolved to be highly diverse in both shape and sequences ([@bib181]; [@bib128]; [@bib179]). Similarly, the G-protein-binding regions are also quite diverse in sequences, modulating the activity of different signalling pathways by recruiting dozens of heterotrimeric G proteins ([@bib143]; [@bib31]; [@bib106]), arrestins ([@bib42]; [@bib209]; [@bib198]; [@bib98]), GPCR kinases ([@bib84]) in a ligand-specific manner. Residues that connect the ligand-binding pocket to the G-protein-coupling region are significantly more conserved ([@bib5]; [@bib63]), with evolutionarily conserved sequence motifs (CWxP \[[@bib32]; [@bib37]; [@bib190]; [@bib171]; [@bib55]; [@bib129]; [@bib53]; [@bib176]\], PIF \[[@bib5]; [@bib65]; [@bib155]; [@bib74]\] Na^+^ pocket \[[@bib32]; [@bib37]; [@bib103]; [@bib202]; [@bib35]; [@bib77]; [@bib185]; [@bib192]; [@bib201]; [@bib14]\], NPxxY \[[@bib143]; [@bib37]; [@bib190]; [@bib129]; [@bib53]; [@bib176]; [@bib155]; [@bib14]; [@bib182]\] and DRY \[[@bib155]; [@bib2]; [@bib69]; [@bib36]; [@bib151]; [@bib157]; [@bib203]\]) scattered in the intracellular half of the 7TM domain ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

![An increasing number of reported class A GPCR structures facilitates studies on common activation mechanism.\
(**a**) Distribution of structures in different states in the non-olfactory class A GPCR tree as of October 1, 2018. (**b**) Common GPCR activation mechanism and the residue-level triggers are not well understood.\
Figure 1---source data 1.The released class A GPCR structures (as of October 1, 2018).\
Figure 1---source data 2.Disease mutations occurred in class A GPCRs.](elife-50279-fig1){#fig1}

GPCR activation is agonist binding induced G-protein recruitment ([@bib32]; [@bib20]; [@bib113]; [@bib166]; [@bib25]). It is an allosteric process ([@bib45]; [@bib119]; [@bib19]; [@bib97]), transducing various external stimuli into cellular responses. Understanding the activation mechanism of GPCR is of paramount importance in pharmacology research and drug discovery. Tremendous previous efforts, involving sequence analysis, structural, biophysical, biochemical and computational approaches such as X-ray ([@bib140]; [@bib150]; [@bib187]; [@bib11]; [@bib127]; [@bib177]; [@bib144]; [@bib137]; [@bib148]; [@bib80]; [@bib17]; [@bib44]; [@bib16]; [@bib9]; [@bib104]; [@bib188]; [@bib165]; [@bib206]), NMR ([@bib201]; [@bib14]; [@bib130]; [@bib94]; [@bib66]; [@bib163]; [@bib200]; [@bib158]), Cryo-EM ([@bib102]; [@bib207]; [@bib15]; [@bib145]), labeling biosensors ([@bib62]; [@bib175]), FRET ([@bib47]; [@bib49]; [@bib152]), BRET ([@bib95]; [@bib100]; [@bib132]), DEER ([@bib193]; [@bib178]; [@bib30]), molecular dynamic simulations ([@bib202]; [@bib30]; [@bib27]; [@bib28]; [@bib29]; [@bib121]; [@bib7]; [@bib82]; [@bib21]; [@bib2]), evolutionary tracing ([@bib111]; [@bib154]; [@bib147]), molecular docking ([@bib88]; [@bib69]; [@bib85]; [@bib122]; [@bib36]; [@bib151]; [@bib110]; [@bib22]) and mutagenesis ([@bib155]; [@bib167]; [@bib116]; [@bib141]; [@bib58]) have been made to study the allosteric nature of GPCRs including but not limited to receptor activation ([@bib190]; [@bib171]; [@bib176]; [@bib182]; [@bib67]; [@bib131]; [@bib59]; [@bib24]; [@bib96]), G protein activation ([@bib176]; [@bib39]; [@bib38]; [@bib41]; [@bib46]; [@bib60]; [@bib61]; [@bib189]), biased agonism ([@bib120]; [@bib133]; [@bib153]; [@bib161]; [@bib168]; [@bib191]; [@bib195]; [@bib194]; [@bib118]), ligand efficiency ([@bib47]; [@bib41]; [@bib108]; [@bib162]; [@bib199]), allosteric modulators ([@bib172]; [@bib87]; [@bib99]; [@bib107]; [@bib109]; [@bib146]; [@bib156]; [@bib197]; [@bib208]; [@bib134]; [@bib70]; [@bib54]; [@bib105]; [@bib12]; [@bib135]), and inverse agonism ([@bib12]; [@bib135]; [@bib56]; [@bib125]; [@bib139]; [@bib157]). Starting from the first structure of a GPCR-G protein complex (β~2~AR-G~s~) ([@bib143]), the rapidly growing structures of receptor-G-protein complex have provided excellent opportunity to better understand receptor conformation changes upon activation. Meanwhile, mutagenesis studies on different receptors also identified functional roles of key residues in receptor activation, one good example is CXCR4 ([@bib190]), where a large-scale mutagenesis study covering all 352 residues of the receptor identified 41 amino acids that are required for signalling induced by agonist CXCL12. Notably, family-wide analysis on GPCR activation with the concept of residue contacts ([@bib181]; [@bib39]; [@bib78]) have revealed the converged activation pathway near the G-protein-coupling region ([@bib182]) and selectivity determinants of GPCR--G-protein binding ([@bib39]). While these studies have provided key insights into GPCR activation mechanism for individual receptors or specific motifs, a family-wide common activation mechanism that directly connect ligand-binding pocket and G-protein-coupling region has yet to be discovered. Although it is well established that outward movement of transmembrane helix 6 (TM6) upon ligand binding is a common feature of receptor activation, the residue level changes that trigger the movement of TM6 remain less well understood ([Figure 1b](#fig1){ref-type="fig"}).

Receptor activation requires global reorganization of residue contacts as well as water-mediated interactions ([@bib203]; [@bib204]; [@bib183]). Since prior studies primarily investigated conformational changes through visual inspection ([@bib171]; [@bib176]) or through the presence or absence of non-covalent contacts between residues ([@bib182]; [@bib39]), we reasoned that one could gain comprehensive knowledge about mechanism of receptor activation by developing approaches that can capture not just the presence or absence of a contact but also subtle, and potentially important alterations in conformations upon receptor activation.

Results {#s2}
=======

A residue-residue contact score-based framework to characterize GPCR conformational changes {#s2-1}
-------------------------------------------------------------------------------------------

To address this, we developed an approach to rigorously quantify residue contacts in proteins structures and infer statistically significant conformational changes. We first defined a residue-residue contact score (RRCS) which is an atomic distance-based calculation that quantifies the strength of contact between residue pairs ([@bib128]) by summing up all possible inter-residue heavy atom pairs ([Figure 2a](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). We then defined ∆RRCS, which is the difference in RRCS of a residue pair between any two conformational states of a receptor that quantitatively describes the rearrangements of residue contacts ([Figure 2b](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}). While RRCS can be 0 (no contact) or higher (stronger contact), ∆RRCS can be negative (loss in strength of residue contact), positive (gain in strength of residue contact) or 0 (no change in strength of residue contact). To capture the entirety of conformational changes in receptor structure upon activation, we computed the ∆RRCS between the active and inactive states of a receptor and defined two types of conformational changes ([Figure 2c](#fig2){ref-type="fig"}): (i) switching contacts: these are contacts that are present in the inactive state but lost in the active state (or vicw versa) such as loss of intra-helical contacts between D/E^3×49^ (GPCRdb numbering \[[@bib64]\]) and R^3×50^, and gain of inter-helical hydrophobic contacts between residues at 3×40 and 6×48 upon receptor activation; and (ii) repacking contacts: these are contacts that result in an increase or decrease in residue packing such as the decreased packing of intra-helical side-chain contacts between W^6×48^ and F^6×44^, and the increase in inter-helical residue packing due to the translocation of N^7×49^ toward D^2×50^ upon receptor activation. In this manner, we quantified the global, local, major and subtle conformational changes in a systematic way (i.e. inter-helical and intra-helical, switching and repacking contacts).

![Understanding GPCR activation mechanism by RRCS and ∆RRCS.\
(**a**) Comparison of residue contact (RC) ([@bib182]) and residue residue contact score (RRCS) calculations. RRCS can describe the strength of residue-residue contact quantitatively in a much more accurate manner than the Boolean descriptor RC. (**b**) RRCS and ΔRRCS calculation for a pair of active and inactive structures can capture receptor conformational change upon activation. (**c**) Two types of conformational changes (i.e. switching and repacking contacts) can be defined by RRCS to quantify the global, local, major and subtle conformational changes in a systematic way. (**d**) Two criteria of identifying conserved residue rearrangements upon receptor activation by RRCS and ΔRRCS. Thirty-four residues pairs were identified based on the criteria (see Materials and methods, [Figure 2---source datas 1](#fig2sdata1){ref-type="supplementary-material"} and [2](#fig2sdata2){ref-type="supplementary-material"} for details), only six of them were discovered before ([@bib182]).\
Figure 2---source data 1.Calculated RRCS of 34 residue pairs constituting the common activation pathway for released class A GPCR structures.\
Figure 2---source data 2.Thirty-four residue pairs show conserved rearrangements of residue contacts upon activation.](elife-50279-fig2){#fig2}

We then analyzed 234 structures of 45 class A GPCRs that were grouped into three categories ([Figure 1a](#fig1){ref-type="fig"}): (i) antagonist- or inverse agonist-bound (inactive; 142 structures from 38 receptors); (ii) both agonist- and G protein/G protein mimetic-bound (fully active; 27 structures from eight receptors); and (iii) agonist-bound (intermediate; 65 structures from 15 receptors). Among them, six receptors \[rhodopsin (bRho) ([@bib101]; [@bib18]), β~2~-adrenergic receptor (β~2~AR) ([@bib143]; [@bib17]), M2 muscarinic receptor (M2R) ([@bib87]; [@bib48]), μ-opioid receptor (μOR) ([@bib112]; [@bib57]), adenosine A~2A~ receptor (A~2A~R) ([@bib11]; [@bib68]) and κ-opioid receptor (κ-OR) ([@bib196]; [@bib13])\] have both inactive- and active-state crystal structures available. Given that ∆RRCS can capture major and subtle conformational changes, we computed RRCS for all structures and ∆RRCS for the six pairs of receptors and investigated the existence of a common activation pathway (i.e. a common set of residue contact changes) across class A GPCRs. Two criteria ([Figure 2d](#fig2){ref-type="fig"}; further details in Materials and methods) were applied to identify conserved rearrangements of residue contacts: (i) equivalent residue pairs show a similar and substantial change in RRCS between the active and inactive state structures of each of the six receptors (i.e. the same sign of ∆RRCS and \|∆RRCS\| \> cut-off for all receptors) and (ii) family-wide comparison of the RRCS for the 142 inactive and 27 active state structures shows a statistically significant difference (p\<0.001; two sample *t*-test). This allowed us to reliably capture both the major rearrangements as well as subtle but conserved conformational changes at the level of individual residues in diverse GPCRs in a statistically robust and significant manner. Consistent with this, a comparison with earlier studies revealed that the RRCS based approach is able to capture a larger number of conserved large-scale and subtle changes in residues contacts ([Figure 2d](#fig2){ref-type="fig"}) that would have been missed by visual inspection or residue contact presence/absence criteria alone (see Materials and methods for conceptual advance of this approach and detailed comparison).

Discovery of a common and conserved receptor activation pathway {#s2-2}
---------------------------------------------------------------

Remarkably, for the first time, our analysis of the structures allowed the discovery of a common and conserved activation pathway that directly links ligand-binding pocket and G protein-coupling regions in class A GPCRs ([Figure 3](#fig3){ref-type="fig"}). The pathway is comprised of 34 residue pairs (formed by 35 residues) with conserved rearrangement of residue contacts upon activation ([Figure 2d](#fig2){ref-type="fig"}), connecting several well-known but structurally and spatially disconnected motifs (CWxP, PIF, Na^+^ pocket, NPxxY and DRY) all the way from the extracellular side (where the ligand binds) to the intracellular side (where the G-protein binds). Inspection of the rewired contacts as a ∆RRCS network reveals that the conserved receptor activation pathway is of modular nature and involves conformational changes in four layers. In layer 1, there is a conserved signal initiation step involving changes in residue contacts at the bottom of the ligand-binding pocket and Na^+^ pocket. In layer 2, critical hydrophobic contacts are broken (*i.e.*, opening of the hydrophobic lock). In layer 3, microswitch residues (6×37, Y^7×53^) are rewired and in layer 4, the residue R^3×50^ and G protein contacting positions are rewired, making them competent to bind to G protein on the cytosolic side ([Figure 3](#fig3){ref-type="fig"}). Strikingly, recently released cryo-EM structures of four receptors (5-HT~1B~, rhodopsin, A~1~R and µOR) in complex with G~i/o~([@bib46]; [@bib43]; [@bib73]; [@bib81]; [@bib26]; [@bib177]) also support the conservation of contacts involving these 34 residue pairs ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}). These observations highlight the conserved and common nature of a previously undescribed activation pathway linking ligand binding to G-protein coupling, regardless of the subtypes of intracellular effectors (*i.e.*, G~s~ ([@bib143]; [@bib11]), G~i/o~([@bib46]; [@bib43]; [@bib73]; [@bib81]; [@bib26]; [@bib177]), arrestin ([@bib209]; [@bib72]) or G-protein mimetic nanobody/peptide ([@bib144]; [@bib87]; [@bib18]; [@bib57]; [@bib13]), [Figure 4a](#fig4){ref-type="fig"}).

![Common activation pathway of class A GPCRs.\
Node represents structurally equivalent residue with the GPCRdb numbering ([@bib64]) while the width of edge is proportional to the average ∆RRCS among six receptors (bRho, β~2~AR, M2R, µOR, A~2A~R and κ-OR). Four layers were qualitatively defined based on the topology of the pathway and their roles in activation: signal initiation (layer 1), signal propagation (layer 2), microswitches rewiring (layer 3) and G-protein coupling (layer 4).](elife-50279-fig3){#fig3}

![The common activation mechanism is the shared portion of various downstream pathways of different class A GPCRs.\
(**a**) Intracellular binding partners used in the active state structures. (**b**) Comparison of RRCS for active (green) and inactive (orange) states of eight receptors with different intracellular binding partners, including four recently solved cryo-EM structures of G~i/o~-bound receptors (5-HT~1B~ receptor, rhodopsin, A~1~R and µOR) ([@bib177]; [@bib43]; [@bib73]; [@bib81]; [@bib26]) whose resolutions were low (usually ≥3.8 Å for the GPCR part). Nevertheless, almost all conserved residue rearrangements in the pathway can be observed from them. Three of 34 residues pairs were shown here, see [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"} for the remaining 31 residue pairs.](elife-50279-fig4){#fig4}

Collectively, these findings illustrate how a combination of intra-helical and inter-helical switching contacts as well as repacking contacts underlies the common activation mechanism of GPCRs.

Molecular insights into key steps of the common activation pathway {#s2-3}
------------------------------------------------------------------

Receptor activation is triggered by ligand binding and is characterised by movements of different transmembrane helices. How does ligand-induced receptor activation connect the different and highly conserved motifs, rewire residue contacts and result in the observed changes in transmembrane helices? To this end, we analyzed the common activation pathway in detail and mapped, where possible, how they influence helix packing, rotation and movement ([Figure 3](#fig3){ref-type="fig"}). A qualitative analysis suggests the presence of four layers of residues in the pathway linking the ligand binding residues to the G-protein-binding region.

Layer 1: We did not see a single ligand-residue contact that exhibits conserved rearrangement, which accurately reflects the diverse repertoire of ligands that bind GPCRs ([@bib75]; [@bib181]; [@bib128]) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Instead, as a first common step, extracellular binding of diverse agonists converges to trigger an identical alteration of the transmission switch (3×40, 5×51, 6×44 and 6×48) and Na^+^ pocket (2×50, 3×39, 7×45 and 7×49). Specifically, the repacking of an intra-helical contact between residues at 6×48 and 6×44, together with the switching contacts of residue at 3×40 toward 6×48 and residue at 5×51 toward 6×44, contract the TM3-5-6 interface in this layer. This reorganization initializes the rotation of the cytoplasmic end of TM6. The collapse of Na^+^ pocket leads to a denser repacking of the four residues (2×50, 3×39, 7×45 and 7×49), initiating the movement of TM7 toward TM3. Remarkably, a recent NMR study on A~2A~R ([@bib32]) demonstrated the strong coupling between allosteric switch D^2×50^ and toggle switch W^6×48^, which is consistent with the present observation.

Layer 2: In parallel with these movements, two residues (6×40 and 6×41) switch their contacts with residue at 3×43, and form new contacts instead with residues at 5×58 and 5×55, respectively. Residues at 3×43, 6×40 and 6×41 are mainly composed of hydrophobic amino acids and referred as hydrophobic lock ([@bib190]; [@bib171]; [@bib50]; [@bib115]). Its opening loosens the packing of TM3-TM6 and facilitates the outward movement of the cytoplasmic end of TM6, which is necessary for receptor activation. Additionally, N^7×49^ develops contacts with residue at 3×43 from nothing, facilitating the movement of TM7 toward TM3.

Layer 3: Upon receptor activation, Y^7×53^ loses its inter-helical contacts ([@bib182]) with residues at 1×53 and 8×50, and forms new contacts with residues at 3×43, 3×46 and R^3×50^, which were closely packed with residues in TM6. Thus, the switching of contacts by Y^7×53^ strengthens the packing of TM3-TM7, while the packing of TM3-TM6 is further loosened with the outward movement of TM6.

Layer 4: Finally, the restrains on R^3×50^, including more conserved, local intra-helical contacts with D(E)^3×49^ and less conserved ionic lock with D(E)^6×30^, are eliminated and R^3×50^ is released. Notably, the switching contacts between R^3×50^ and residue at 6×37 are essential for the release of R^3×50^, which breaks the remaining contacts between TM3 and TM6 in the cytoplasmic end and drives the outward movement of TM6. The rewired contacts of R^3×50^ and other G-protein contacting positions (3×53, 3×54, 5×61 and 6×33) make the receptor competent to bind to G protein on the cytosolic side.

Together, these findings demonstrate that the intra-helical/inter-helical and switching/repacking contacts between residues is not only critical to reveal the continuous and modular nature of the activation pathway, but also to link residue-level changes to transmembrane helix-level changes in the receptor.

Common activation pathway induced changes in TM helix packing {#s2-4}
-------------------------------------------------------------

To capture the patterns in the global movements of transmembrane helices, all inter-helical residues pairs in the common activation pathway were used to describe the inter-helical contacts between the cytoplasmic end of TM3 and TM6 as well as TM3 and TM7 ([Figure 5a](#fig5){ref-type="fig"}). Analysis of the RRCS~TM3-TM7~ (X-axis) and RRCS~TM3-TM6~ (Y-axis) for each of the 234 class A GPCR structures revealed distinct compact clusters of inactive and active states. Surprisingly, the inactive state has zero or close to zero RRCS~TM3-TM7~ regardless of the wide distribution of RRCS~TM3-TM6~. In contrast, the active state has a high RRCS~TM3-TM7~ and strictly zero RRCS~TM3-TM6~. Thus, receptor activation from inactive to active state occurs as a harmonious process of inter-helical contact changes: elimination of TM3-TM6 contacts, formation of TM3-TM7 contacts and repacking of TM5-TM6 ([Figure 5b](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In terms of global conformational changes, the binding of diverse agonists converges to trigger outward movement of the cytoplasmic end of TM6 and inward movement of TM7 toward TM3 ([@bib143]; [@bib129]; [@bib182]), thereby creating an intracellular crevice for G protein coupling ([Figure 5b](#fig5){ref-type="fig"}).

![Common activation model of class A GPCRs reveals major changes upon GPCR activation.\
(**a**) Active and inactive state structures form compact clusters in the 2D inter-helical contact space: RRCS~TM3-TM7~ (X-axis) and RRCS~TM3-TM6~ (Y-axis). GPCR activation is best described by the outward movement of TM6 and inward movement of TM7, resulting in switch in the contacts of TM3 from TM6 to TM7. (**b**) Common activation model for class A GPCRs. Residues are shown in circles, conserved contact rearrangements of residue pairs upon activation are denoted by lines.](elife-50279-fig5){#fig5}

It is noteworthy that the common activation pathway we discovered in this study is not the only pathway that connecting extracellular ligand-binding and intracellular effector coupling for class A GPCRs ‒ it is likely to be a shared portion of various activation pathways of GPCR members belonging to this class ‒ each receptor still has its unique receptor-, ligand- and effector-specific activation pathways. In fact, research on this subject has boosted the discovery of selective and biased ligands ([@bib120]; [@bib133]; [@bib153]; [@bib161]; [@bib168]; [@bib191]; [@bib195]; [@bib194]).

As shown in [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}, collapse of the Na^+^ pocket leads to a denser repacking of six residues (five residue pairs), reflected by higher RRCS~sodium_pocket~ scores in active state than that in inactive state structures. Recently, the crystal structures (5X33 \[[@bib56]\], 6BQG \[[@bib139]\] and 6K1Q \[[@bib125]\]) whose ligand (inverse agonist) diffuses deep in ligand-binding pocket or even occupies the sodium binding pocket (below D^2×50^) were reported. These inverse agonists disrupt the collapse of Na^+^ pocket by blocking the rotation of W^6×48^ and/or taking the space of Na^+^, and stabilize the receptors in an inactive state. Indeed, these inactive state structures showed zero RRCS~TM3-TM7~ but high RRCS~TM3-TM6~ scores. The inverse agonism are not only consistent with both our activation model and mutagenesis experiments, but also supported by the NMR study of A~2A~R ([@bib32]). This study demonstrated the role of D52^2×50^ as an allosteric link between the orthosteric ligand-binding site and the intracellular signaling surface, revealing strong interactions with the toggle switch W246^6×48^.

Experimental validation of the modular nature of the common activation pathway {#s2-5}
------------------------------------------------------------------------------

Based on the knowledge of the common activation pathway, one would expect that mutations of residues in the pathway are likely to severely affect receptor activation. The two extreme consequences are constitutive activation (without agonist binding) or inactivation (abolished signalling). To experimentally test this hypothesis, we systematically designed site-directed mutagenesis for residues in the pathway on a prototypical receptor A~2A~R, aiming to create constitutively activating/inactivating mutations (CAM/CIM), by promoting/blocking residue and helix level conformational changes revealed in the pathway. 6/15 designed CAMs and 15/20 designed CIMs were validated by functional cAMP accumulation assays, and none of them were reported before for A~2A~R ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). The design of functional active/inactive mutants has been very challenging. However, the knowledge of common activation pathway of GPCRs presented here greatly improves the success rate. The mechanistic interpretation of 21 successful predicted mutants is explained below. We also discussed the 14 unsuccessful predictions in [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}. Besides, we extended mutagenesis studies to G~s~-coupled 5-HT~7~ and G~i~-coupled 5-HT~1B~ receptors by designing CAM/CIMs in residues at 3×40, 3×43, 6×40, 6×44, and 7×49 ([Figure 6---figure supplement 2](#fig6s2){ref-type="fig"}).

![Experimental validation of the common activation mechanism.\
(**a**) cAMP accumulation assay and (**b**) radioligand binding assay: both validated the common activation pathway-guided design of CAMs/CIMs for A~2A~R. Wildtype (WT), CAMs and CIMs are shown in black, green and orange, respectively. (**c**) Mechanistic interpretation of common activation pathway-guided CAMs/CIMs design. N.D.: basal activity was too high to determine an accurate EC~50~ value.\
Figure 6---source data 1.Functional and ligand binding properties of A~2A~R mutations.\
Figure 6---source data 2.Analysis of the 14 unsuccessful predictions of A~2A~R CAMs/CIMs.ΔStability (\>0 means destabilized;\<0 means stabilized) is the change of receptor stability when a mutation was introduced, calculated by Residue Scanning module in BioLuminate ([@bib6]). WT, wild-type.](elife-50279-fig6){#fig6}

In layer 1, the mutation I92^3×40^N likely stabilizes the active state by forming amide-π interactions with W246^6×48^ and hydrogen bond with the backbone of C185^5×461^, which rewires the packing at the transmission switch and initiates the outward movement of the cytoplasmic end of TM6; this mutation elevated the basal cAMP level by sevenfold. Conversely, I92^3×40^A would reduce the favorable contacts with W^6×48^ upon activation, which retards the initiation of the outward movement of TM6; this mutation resulted in a decrease in both basal cAMP level \[71% of wild-type (WT)\] and agonist potency (eightfold). Another example is the residue at 6×44, the mutation F242^6×44^R would stabilize the inactive state by forming salt bridge with D52^2×50^, which blocks the rotation of TM6 and thus abolishes G~s~ coupling; indeed this mutation greatly reduced basal cAMP level (to 63% WT) and agonist potency (by 374-fold). In contrast, F242^6×44^A would reduce contacts with W246^6×48^, loosen TM3-TM6 contacts, diminish the energy barrier of TM6 release and make outward movement of TM6 easier; consistently this mutation elevated the basal cAMP level (by twofold) and increased the agonist potency (by eightfold). Mutations of residues forming the Na^+^ pocket, such as D52^2×50^A and N280^7×45^R, would destroy the hydrogen bond network at the Na^+^ pocket and retard the initiation of the inward movement of TM7. These mutations completely abolished agonist potency and greatly reduced the basal cAMP level (to 80% and 78% of WT, respectively).

In layer 2, the mutations L95^3×43^A/R and I238^6×40^Y would loosen the hydrophobic lock, weaken TM3-TM6 contacts, promote the outward movement of cytoplasmic end of TM6 and eventually make receptor constitutively active; this is reflected by remarkably high basal cAMP production (28-, 2- and 11-fold increase, respectively). Notably, mutations at/near the Na^+^ pocket, L48^2×46^R and N284^7×49^K, could lock the Na^+^ pocket at inactive packing mode by introducing salt bridge with D52^2×50^, thus blocking the inward movement of TM7 toward TM3. As expected, these mutations completely abolished agonist potency. The CIMs at/near the Na^+^ pocket (from both layers 1 and 2) reflect that the subtle inward movement of TM7 towards TM3 is essential for receptor activation, which is often underappreciated and overshadowed by the movement of TM6. In line with this, two mutations on TM7, N284^7×49^A and Y288^7×53^A, attenuate the TM3-TM7 contacts upon activation and completely abolished or greatly reduced (by 16-fold) agonist potency, respectively.

In layer 3, I98^3×46^A likely reduces contacts with Y288^7×53^, weakens the packing between TM3-TM7, and retards the movement of TM7 toward TM3; similarly, L235^6×37^A would reduce contacts with F201^5×62^, weaken the packing between TM5-TM6, and makes the TM6 movement toward TM5 more difficult. In line with the interpretation, these mutations resulted in reduced basal cAMP level (72% and 71% WT, respectively) and decreased agonist potency (23- and 4-fold, respectively). These results are consistent with previous findings on vasopressin type-2 receptor (V2R) ([@bib182]).

In layer 4, D101^3×49^N likely diminishes its intra-helical interaction with R102^3×50^ and thus makes the release of the latter easier, which in turn promotes G-protein recruitment. Consistent with this possibility, this mutation led to a greatly elevated basal cAMP level (eightfold).

Despite these A~2A~R mutants greatly affect receptor activation, our radioligand binding assay shows that they generally retain the agonist binding ability, with the exception of two CIMs: W246^6×48^A and N284^7×45^K ([Figure 6b,c](#fig6){ref-type="fig"} and [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). This suggests that the common activation pathway is of modular nature and that such an organization allows for a significant number of residues involved in agonist binding to be uncoupled from receptor activation/inactivation and G-protein binding.

As shown in [Figure 6---figure supplements 2](#fig6s2){ref-type="fig"} and 5-HT~7~ receptor mutations F336^6×44^R and N380^7×49^K completely abolished agonist potency and greatly reduced the basal cAMP level, which is remarkably consistent with the observation on A~2A~R, highlighting the crucial role of the highly conserved residues F^6×44^ and N^7×49^. Beyond G~s~-coupled A~2A~R and 5-HT~7~ receptor, we also validated this mutation design in G~i~-coupled 5-HT~1B~ receptor. Indeed, two CIMs, I137^3×40^N and F323^6×44^H greatly reduced receptor-mediated G~i~ activity compared to WT, whereas three CAMs, L173^3×43^A in G~s~-coupled 5-HT~7~ receptor, F323^6×44^A and I137^3×40^A in G~i~-coupled 5-HT~1B~ receptor, were verified to promote their basal activities, consistent with the observation on CAMs (L95^3×43^A, F242^6×44^A and I92^3×40^A) designed for A~2A~R.

The common pathway allows mechanistic interpretation of mutations {#s2-6}
-----------------------------------------------------------------

Four hundred thirty five disease-associated mutations were collected, among which 28% can be mapped to the common activation pathway, much higher than that to the ligand-binding and G-protein-binding regions (20% and 7%, respectively) ([Figure 7a,b](#fig7){ref-type="fig"}). Furthermore, 272 CAMs/CIMs from 41 receptors ([Figure 7c](#fig7){ref-type="fig"}) were mined from the literature for the 14 hub residues (i.e. residues that have more than one edges in the pathway).

![Importance of the common activation pathway in pathophysiological and biological contexts.\
(**a**) Comparison of disease-associated mutations in the common activation pathway (further decomposed into layers 1--4), ligand-binding pocket, G-protein-coupling region and other regions. Red line denotes the mean value. (**b**) Mapping of disease-associated mutations in class A GPCRs to the common activation pathway. (**c**) Key roles of the residues constituting the common activation pathway have been reported in numerous experimental studies on class A GPCRs. Two hundred seventy two (272) CAMs/CIMs from 41 receptors were mined from the literature for the 14 hub residues (i.e. residues that have more than one edges in the pathway).\
Figure 7---source data 1.Constitutively activating/inactivating mutations for the 14 hub residues in the common activation pathway.](elife-50279-fig7){#fig7}

The average number of disease-associated mutations in the common activation pathway is much higher than that of ligand-binding pocket, G-protein-binding site, and residues in other regions (2.5-, 3.5- and 3.5-fold, respectively), reflecting the enrichment of disease-associated mutations on the pathway ([Figure 7a](#fig7){ref-type="fig"}). Within this pathway, the enrichment of disease mutations and CAMs/CIMs in layers 1 and 2 is noteworthy, which highlights the importance of signal initiation and hydrophobic lock opening, and further supports the modular and hierarchical nature of GPCR activation ([Figures 3](#fig3){ref-type="fig"} and [5b](#fig5){ref-type="fig"}). Notably, for certain residues, such as D^2×50^ and Y^7×53^, only loss-of-function disease mutations or CIMs were observed ([Figure 7](#fig7){ref-type="fig"}), implying they are indispensable for receptor activation and the essential role of TM7 movement ([Figures 3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}).

The functional consequence of these single point mutations can be rationalized by analysing if they are stabilizing/destabilizing the contacts in the common activation pathway or promoting/retarding the required helix movement upon activation ([Figure 7b](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). For example, I130^3×43^N/F (layer 2) in V2R was reported as a gain-/loss-of-function mutation that causes nephrogenic syndrome of inappropriate antidiuresis ([@bib34]) or nephrogenic diabetes insipidus ([@bib138]), respectively. I130^3×43^N/F likely loosens/stabilizes the hydrophobic lock, weakens/strengthens the TM3-TM6 packing and leads to constitutively active/inactive receptors. Another example is T58^1×53^M in rhodopsin, which was reported as a loss-of-function mutation that causes retinitis pigmentosa 4 ([@bib126]). T58^1×53^M likely increases hydrophobic contacts with Y306^7×53^ and P303^7×50^, which retards the inward movement of TM7 towards TM3 and eventually decreases G-protein recruitment. As in the case of disease-associated mutations, CAMs/CIMs that have been previously reported in the literature can also be interpreted by the framework of common activation pathway ([Figure 7---figure supplement 1b](#fig7s1){ref-type="fig"}). For example, F248^6×44^Y in CXCR4 ([@bib190]) was reported as a CIM. This residue likely forms hydrogen bond with S123^3×39^, which blocks the rotation of the cytoplasmic end of TM6, and decreases G-protein engagement.

Not surprisingly, the 35 residues constituting the pathway are highly conserved across class A GPCRs, dominated by physiochemically similar amino acids ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). The average sequence similarity of these positions across 286 non-olfactory class A receptors is 66.2%, significantly higher than that of ligand-binding pockets (31.9%) or signaling protein-coupling regions (35.1%). Together, these observations suggest that the modular and hierarchical nature of the activation pathway allows decoupling of the ligand-binding pocket, G-protein-binding site and the residues contributing to the common activation mechanism. Such an organization of the receptor might facilitate the uneven sequence conservation between different regions of GPCRs, confers their functional diversity in ligand recognition and G-protein binding while still retaining a common activation mechanism.

Discussion {#s3}
==========

Using a novel, quantitative residue contact descriptor, RRCS, and a family-wide comparison across 234 structures from 45 class A GPCRs, we reveal a common activation pathway that directly links ligand-binding pocket and G-protein-coupling region. Key residues that connect the different modules allows for the decoupling of a large number of residues in the ligand-binding site, G-protein contacting region and residues involved in the activation pathway. Such an organization may have facilitated the rapid expansion of GPCRs through duplication and divergence, allowing them to evolve independently and bind to diverse ligands due to removal of the constraint (*i.e.*, between a large number of ligand-binding residues and those involved in receptor activation). This model unifies many previous important motifs and observations on GPCR activation in the literature (CWxP, PIF, Na^+^ pocket, NPxxY, DRY and hydrophobic lock) and is consistent with numerous experimental findings.

We focused on the common activation pathway (i.e. the common part of activation mechanism shared by all class A GPCRs and various intracellular effectors) in this study. Obviously, individual class A receptor naturally has its intrinsic activation mechanism(s), as a result of the diversified sequences, ligands and physiological functions. Indeed, receptor-specific activation pathways (including mechanisms of orthosteric, positive or negative allosteric modulators, biased signaling/selectivity of downstream effectors) have been revealed by both experimental studies including biophysical (such as X-ray, cryo-EM, NMR, FRET/BRET and DEER), biochemical and computational approaches (such as evolutionary trace analysis and molecular dynamics simulations), especially for the prototypical receptors such as rhodopsin, β~2~-adrenergic and A~2A~ receptors. These studies demonstrated the complexity and plasticity of signal transduction of GPCRs. The computational framework we have developed may assist us in better understanding the mechanism of allosteric modulation, G-protein selectivity and diverse activation processes via intermediate states as more GPCR structures become available. While we interpret the changes as a linear set of events, future studies aiming at understanding dynamics could provide further insights into how the common activation mechanism operates in individual receptors.

Given the common nature of this pathway, we envision that the knowledge obtained from this study can not only be used to mechanistically interpret the effect of mutations in biological and pathophysiological context but also to rationally introduce mutations in other receptors by promoting/blocking residue and helix level movements that are essential for activation. Such protein engineering approaches may enable us to make receptors in specific conformational states to accelerate structure determination studies using X-ray crystallography or electron microscopy and functional investigation in the future. The method developed here could also be readily adapted to map allosteric pathways and reveal mechanisms of action for other key biological systems such as kinases, ion channels and transcription factors.

Materials and methods {#s4}
=====================

Glossary {#s4-1}
--------

Transmembrane domains (TMD): the core domain exists in all GPCRs, and consists of seven-transmembrane helices (TM1--7) that are linked by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3).

GPCRdb numbering scheme: a structure-based numbering system for GPCRs ([@bib64]; [@bib63]), an improved version of sequence-based Ballesteros--Weinstein numbering ([@bib5]) that considers structural distortions such as helical bulges or constrictions. The most conserved residue in a helix n is designated n×50, while other residues on the helix are numbered relative to this position.

Node: a point in a network at which lines intersect, branch or terminate. In this case, nodes represent amino acid residues.

Edge: a connection between the nodes in a network. In this case, an edge represents a residue-residue contact.

Hub: a node with two or more edges in a network.

Constitutively activating mutation (CAM): a mutant that could increase the inherent basal activity of the receptor by activating the G-protein-signaling cascade in the absence of agonist.

Constitutively inactivating mutation (CIM): a mutant completely abolishes receptor signalling.

GPCR structure data set {#s4-2}
-----------------------

As of October 1, 2018, there are 234 released structures of 45 class A GPCRs with resolution better than 3.8 Å ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}), which covers 71% (203 out of 286 receptors, including 158 receptors that have no structures but share \>50% sequence similarity in the TMD with the 45 structure-determined receptors) of class A GPCRs ([Figure 1a](#fig1){ref-type="fig"}). Based on the type of bound ligand and effector, these structures could be classified into three states: inactive state (antagonist or inverse agonist-bound, 142 structures from 38 receptors), active state (both agonist- and G protein/G protein mimetic-bound, 27 structures from eight receptors) and intermediate state (only agonist-bound, 65 structures from 15 receptors). In this study, we primarily focused on conformational comparison between inactive- and active- state structures, while also investigating the intermediate state structures. In the structure data set, seven receptors have both inactive and active structures: rhodopsin (bRho), β~2~-adrenergic receptor (β~2~AR), M2 muscarinic receptor (M2R), μ-opioid receptor (μOR), adenosine A~2A~ receptor (A~2A~R), κ-opioid receptor (κ-OR) and adenosine A~1A~ receptor (A~1A~R), the active state structure of which was recently determined by cryo-EM. In addition, 32 receptors have either inactive or active structures ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}).

Calculation of residue-residue contact score (RRCS) {#s4-3}
---------------------------------------------------

We developed a much finer distance-based method (than coarse-grained Boolean descriptors such as contact map and residues contact \[[@bib182]; [@bib78]; [@bib33]; [@bib184]; [@bib186]; [@bib1]\]), namely residue-residue contact score (RRCS). For a pair of residues, RRCS is calculated by summing up a plateau-linear-plateau form atomic contact score adopted from GPCR--CoINPocket ([@bib128]; [@bib88]; [@bib92]; [@bib90]; [@bib89]; [@bib91]; [@bib114]) for each possible inter-residue heavy atom pairs ([Figure 2---figure supplement 1a](#fig2s1){ref-type="fig"}). GPCR--CoINPocket is a modified version of the hydrophobic term of ChemScore ([@bib33]; [@bib184]) that has been successfully used to describe hydrophobic contribution to binding free energy between ligand and protein. RRCS can describe the strength of residue-residue contact quantitatively in a much more accurate manner than Boolean descriptors ([@bib182]; [@bib39]). For example, Boolean descriptors do not capture side chain repacking if the backbone atoms of the two residues are close to each other (e.g. translocation of Y^7×53^ away from residue at 2×43 upon GPCR activation) and local contacts involving adjacent residues (residues within four/six amino acids in protein sequence) (e.g., disengagement between D/E^3×49^ and R^3×50^), while both cases can be well reflected by the change of RRCS ([Figure 2c](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}).

All RRCS data can be found in [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}. The computational details are described as below:

1.  For the residue pairs between adjacent residues that are within four amino acids in protein sequence, only side chain heavy atom pairs were considered, atom pairs involving in backbone atoms (Cα, C, O, N) were excluded, since the latter seldom change during GPCR activation. For other residue pairs, all possible heavy atom pairs (including backbone atoms) were included when calculating RRCS.

2.  Atomic contact scores are solely based on interatomic distance, and they are treated equally without weighting factors such as atom type or contact orientation. In principle, weighting of atomic contact by atom type and/or orientation would improve residue-residue contact score. However, parameterization of atom type or contact orientation is relatively arbitrary, subjective and complicated, especially considering the lipid bilayer environment surrounding GPCRs. Our preliminary study for 12 structures from six receptors (bRho, β~2~AR, M2R, µOR, A~2A~R and κ-OR) revealed that amino acids with hydrophobic side chains (one-letter code: A, V, I, L, M, P, F, Y, W) contribute to the majority (\~88%) of residue pairs. Meanwhile, ionic lock opening of well-known motif DRY upon receptor activation can be adequately reflected by RRCS change between D/E^3×49^ and R^3×50^. These results suggest that interatomic distance-dependent residue pair contact score may represent an acceptable approximation of actual (either hydrophobic or charge-charge) interaction energies ([@bib128]) and is accurate enough for identifying conserved rearrangements of residue contacts upon receptor activation.

3.  The quality of structures is extremely important for RRCS calculation. We adopted two criteria to exclude unreliable structures and residues: (a) crystal structures whose resolution is ≥3.8 Å. Structures in this category are: 5DGY (7.70 Å), 2I37 (4.20 Å), 2I36 (4.10 Å), 5TE5 (4.00 Å), 4GBR (4.00 Å), 5NJ6 (4.00 Å), 5V54 (3.90 Å), 2I35 (3.80 Å), 5D5B (3.80 Å), 4XT3 (3.80 Å); (b) residues whose residue-based real-space R-value (RSR \[[@bib71]\]) is greater than 0.35. RSR is measure of how well 'observed' and calculated electron densities agree for a residue. RSR ranges from 0 (perfect match) to 1 (no match); RSR greater than 0.4 indicates a poor fit ([@bib159]). Here we adopted a stricter cut-off, 0.35. Among the 234 class A GPCR structures, 156 have available RSR information ([@bib79]) (<http://eds.bmc.uu.se>), with 8.8% residues have RSR \>0.35 and they are omitted in our analysis. For the 35 residues that constitute the common activation pathway, 255 out of 5460 RSR data points (\~4.7%, lower than 8.8% for all residues) were omitted for having RSR values \> 0.35.

4.  For structures with multiple chains, RRCS were the average over all chains. For residues with multiple alternative conformations, RRCS was the sum of individual values multiplied by the weighting factor: occupancy value extracted from PDB files. Small molecule/peptide ligand, or intracellular binding partner (G protein or its mimetic) was treated as a single residue.

5.  For the family-wide comparison of conformational changes upon activation, structurally equivalent residues are numbered by GPCRdb numbering scheme ([@bib64]; [@bib63]). Of the 35 residues in the common activation pathway, their GPCRdb numbering in all structures is almost identical to the Ballesteros--Weinstein numbering ([@bib5]), the exceptions are residues at 6×37, 6×41 and 6×44 for five receptors: FFAR1, P2Y~1~, P2Y~12~, F2R and PAR2, which are all from the delta branch of class A family.

Identification of conserved rearrangements of residue contacts upon activation {#s4-4}
------------------------------------------------------------------------------

Using RRCS, structural information of TMD and helix eight in each structure can be decomposed into 400 \~ 500 residue pairs with positive RRCS. ∆RRCS, defined as RRCS~active~ − RRCS~inactive~, reflects the change of RRCS for a residue pair from inactive- to active- state ([Figure 2b--d](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1b](#fig2s1){ref-type="fig"}). To identify residue pairs with conserved conformational rearrangements upon activation across class A GPCRs, two rounds of selections ([Figure 2d](#fig2){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}) were performed: (i) identification of conserved rearrangements of residue contacts upon activation for six receptors (bRho, β~2~AR, M2R, μOR, A~2A~R and κ-OR), that is equivalent residue pairs show a similar and substantial change in RRCS between the active and inactive state structure of each of the six receptors (the same sign of ∆RRCS and \|∆RRCS\| \> 0.2 for all receptors) and (ii) family-wide RRCS comparison between the 142 inactive and 27 active state structures to identify residues pairs of statistically significant different (p\<0.001; two sample *t*-test) RRCS upon activation.

Round 1. Identification of conserved rearrangements of residue contacts. Six receptors with available inactive- and active- state structures were analyzed using ∆RRCS to identify residue pairs that share similar conformational changes. Twelve representative crystal structures (high-resolution, no mutation or one mutation in TMD without affecting receptor signalling) were chosen in this stage: six inactive state structures (PDB codes 1GZM for bRho, 2RH1 for β~2~AR, 3UON for M2R, 4DKL for μOR, 3EML for A~2A~R and 4DJH for κ-OR) and six active state structures (3PQR for bRho, 3SN6 for β~2~AR, 4MQS for M2R, 5C1M for μOR, 5G53 for A~2A~R and 6B73 for κ-OR) ([Figure 2d](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1c](#fig2s1){ref-type="fig"} and [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). Each receptor has approximately 600 residues pairs that have positive RRCS. Roughly one quarter are newly formed during receptor activation (RRCS~inactive~ = 0 and RRCS~active~ \>0); another quarter lose their contacts upon receptor activation (RRCS~inactive~ \>0 and RRCS~active~ = 0); and the remaining appear in both the inactive- or active- state structures (RRCS~inactive~ \>0 and RRCS~active~ \>0), the contact rearrangement of which can only be reflected by ∆RRCS, but not Boolean descriptors.

To identify residue pairs that share conserved rearrangements of residue contacts upon activation, two steps are performed to qualify residue pairs for the next round. Firstly, residue pairs with same sign of ∆RRCS and \|∆RRCS\| \> 0.2 for all six receptors were identified. There are 32 intra-receptor residues pairs (1×49:7×50, 1×53:7×53, 1×53:7×54, 2×37:2×40, 2×42:4×45, 2×43:7×53, 2×45:4×50, 2×46:2×50, 2×50:3×39, 2×57:7×42, 3×40:6×48, 3×43:6×40, 3×43:6×41, 3×43:7×49, 3×43:7×53, 3×46:6×37, 3×46:7×53, 3×49:3×50, 3×50:3×53, 3×50:6×37, 350:7×53, 3×51:5×57, 5×51:6×44, 5×58:6×40, 5×62:6×37, 6×40:7×49, 6×44:6×48, 7×50:7×55, 7×52:7×53, 7×53:8×50, 7×54:8×50 and 7×54:8×51) and five receptor-G protein/its mimetic residue pairs (3×50:G protein, 3×53:G protein, 3×54:G protein, 5×61:G protein and 6×33:G protein) that meet this criterion. Secondly, we also investigated residue pairs with ∆RRCS that are conserved in five receptors (*i.e.*, with one receptor as exception). Considering there is no Na^+^ pocket for rhodopsin, three residue pairs (2×50:7×49, 6×44:7×45 and 6×48:7×45) around Na^+^ pocket were analyzed for five receptors but not bRho. Additionally, three residue pairs have 0 (3×46:3×50, 5×55:6×41) or negative (7×45:7×49) ∆RRCS for κ-OR but positive ∆RRCS for the other five receptors. As for 3×46:3×50, nanobody-stabilized active structures (β~2~AR: 3P0G, 4LDO, 4LDL, 4LDE, 4QKX; and μOR: 5C1M) generally have lower contact scores (\<0.4) compared with G-protein-bound active-state structures (2.17 for 3SN6 of β~2~AR, 2.57 for 5G53 of A~2A~R and 6.93 for 3PQR of bRho). For these residue pairs, we added newly determined G~i~-bound active A~1A~R and 5-HT~1B~ receptor and found that they have positive ∆RRCS, like other five receptors ([Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}). Thus, these three residue pairs (3×46:3×50, 5×55:6×41 and 7×45:7×49) were retained. Totally, six residue pairs with conserved ∆RRCS in five receptors were rescued. Taken together, 38 intra-receptor residue pairs and five receptor-G protein/its mimetic residue pairs were identified to have conserved rearrangements of residue contacts upon activation.

Round 2. Family-wide conservation analysis of residue contact pattern. To investigate the conservation of residue contact pattern for the 38 intra-receptor residue pairs across these functionally diverse receptors, two-tailed unpaired *t*-test between inactive state (142 inactive structures from 38 receptors) and active state (27 active structures from eight receptors) groups were performed ([Figure 2d](#fig2){ref-type="fig"} and [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}). Thirty one residue pairs have significantly different RRCS between inactive- and active-state (p\<10^−5^). As rhodopsin lacks the Na^+^ pocket, all rhodopsin structures were neglected in the analysis of 3 residue pairs around the pocket (2×50:7×49, 6×44:7×45 and 6×48:7×45), which have good p value (\<10^−3^) for these non-rhodopsin class A GPCRs. Four residue pairs were filtered out in this round due to their poor p value, that is there are no statistically significant difference in RRCS between inactive and active states (p=0.01 for 2×37:2×40, 0.96 for 2×42:4×45, 0.02 for 2×45:4×50 and 0.014 for 2×57:7×42).

Finally, 34 intra-receptor residue pairs ([Figure 2d](#fig2){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"} and [2](#fig4s2){ref-type="fig"}) and five receptor-G-protein residue pairs were identified with conserved rearrangements of residue contacts upon activation, including all six residues pairs identified by the previous RC approaches ([@bib182]).

Sequence analysis of class A GPCRs {#s4-5}
----------------------------------

The alignment of 286 non-olfactory, class A human GPCRs were obtained from the GPCRdb ([@bib64]; [@bib63]). The distribution of sequence similarity/identity across class A GPCRs were extracted from the sequence similarity/identity matrix for different structural regions using 'Similarity Matrix' tool in GPCRdb. The sequence conservation score ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) for all residue positions across 286 non-olfactory class A GPCRs were evaluated by the Protein Residue Conservation Prediction ([@bib10]) tool with scoring method \'Property Entropy\' ([@bib123]). Sequence conservation analysis ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}) were visualized by WebLogo3 ([@bib23]) with sequence alignment files from GPCRdb as the input.

CAM/CIM in class A GPCRs {#s4-6}
------------------------

For the 14 hub residues in the common activation pathway, we collected the functional mutation data from the literature and GPCRdb ([@bib64]; [@bib63]). Mutations with 'more than two fold-increase in basal activity/constitutively active' or 'abolished effect' compared to the wild-type receptor were selected. Together, 272 mutations from 41 class A GPCRs on the 14 hub residues were collected, including the mutations we designed and validated in this study ([Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}).

Disease-associated mutations in class A GPCRs {#s4-7}
---------------------------------------------

To reveal the relationship between disease-associated mutations and related phenotypes of different transmembrane regions ([@bib180]; [@bib174]; [@bib169]; [@bib170]), we collected disease-associated mutation information for all 286 non-olfactory class A GPCRs by database integration and literature investigation. Four commonly used databases (UniProt \[[@bib173]\], OMIM \[[@bib4]\], Ensembl \[[@bib205]\] and GPCRdb \[[@bib64]; [@bib63]\]) were first filtered by disease mutations and then merged. Totally 435 disease mutations from 61 class A GPCRs were collected ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}).

Pathway-guided CAM/CIM design in A~2A~R {#s4-8}
---------------------------------------

We designed mutations for a prototypical receptor A~2A~R, guided by the common activation pathway, aiming to get constitutively active/inactive receptor. Mutations that can either stabilize active or inactive state structures of A~2A~R or promote/block conformational changes upon activation were designed ([Figure 6c](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}) and tested by a functional cAMP accumulation assay. The inactive state structure 3EML and active state structure 5G53 were used. In silico mutagenesis was performed by Residue Scanning module in BioLuminate ([@bib6]). Side-chain prediction with backbone sampling and a cut-off value of 6 Å were applied during the scanning. ΔStability is the change of receptor stability when introducing a mutation. We filtered the mutations by one of the following criteria: (i) ΔStability in active and inactive structures have opposite signs; or (ii) ΔStability in active and inactive structures have the same sign, but favorable interactions such as hydrogen bonds, salt bridge or pi-pi stacking exist in only one structure that can promote/block conformational changes upon activation. Totally, 15 and 20 mutations were predicted to be CAMs and CIMs, respectively. ([Figure 6c](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

cAMP accumulation assays {#s4-9}
------------------------

(i)A~2A~R. The desired mutations were introduced into amino-terminally Flag tag-labeled human A~2A~R in the pcDNA3.1 vector (Invitrogen, Carlsbad, CA). This construct displayed equivalent pharmacological features to that of untagged human receptor based on radioligand binding and cAMP assays ([@bib116]). The mutants were constructed by PCR-based site-directed mutagenesis (Muta-directTM kit, Beijing SBS Genetech Co., Ltd., China). Sequences of receptor clones were confirmed by DNA sequencing. HEK-293 cells (obtained from ATCC and confirmed as negative for mycoplasma contamination) were seeded onto 6-well cell culture plates. After overnight culture, the cells were transiently transfected with WT or mutant DNA using Lipofectamine 2000 transfection reagent (Invitrogen). After 24 hr, the transfected cells were seeded onto 384-well plates (3,000 cells per well). cAMP accumulation was measured using the LANCE cAMP kit (PerkinElmer, Boston, MA) according to the manufacturer's instructions. Briefly, transfected cells were incubated for 40 min in assay buffer (DMEM, 1 mM 3-isobutyl-1-methylxanthine) with different concentrations of agonist \[CGS21680 (179 pM to 50 μM)\]. The reactions were stopped by addition of lysis buffer containing LANCE reagents. Plates were then incubated for 60 min at room temperature and time-resolved FRET signals were measured at 625 nm and 665 nm by an EnVision multilabel plate reader (PerkinElmer). The cAMP response is depicted relative to the maximal response of CGS21680 (100%) at the WT A~2A~R. (ii) 5-HT~1B~ receptor. cAMP accumulation was measured using LANCE cAMP kit (PerkinElmer). Briefly, HEK293T (obtained from and certified by the Cell Bank at the Chinese Academy of Science and confirmed as negative for mycoplasma contamination) cells were transfected with plasmids bearing WT or mutant 5-HT~1B~ receptor. Cells were collected 24 hr post-transfection and used to seed white poly-D-lysine coated 384-well plates at a density of 2,000 cells per well. Cells were incubated for a further 24 hr at 37°C. Cells were then incubated for 30 min in assay buffer (HBSS, 5 mM HEPES, 0.1% BSA, 0.5 mM 3-isobutyl-1-methylxanthine) with constant Forsklin (800 nM) and different concentrations of dihydroergotamine (DHE, 0.64 pM to 50 nM) at 37°C. The reactions were stopped by addition of lysis buffer containing LANCE reagents. Plates were then incubated for 60 min at room temperature, and time-resolved FRET signals were measured after excitation at 620 nm and 650 nm by EnVision (PerkinElmer).

CGS21680 binding assay {#s4-10}
----------------------

CGS21680 (a specific adenosine A~2A~ subtype receptor agonist) binding was analyzed using plasma membranes prepared from HEK-293 cells transiently expressing WT and mutant A~2A~Rs. Approximately 1.2×10^8^ transfected HEK-293 cells were harvested, suspended in 10 ml ice-cold membrane buffer (50 mM Tris-HCl, pH 7.4) and centrifuged for 5 min at 700 ***g***. The resulting pellet was resuspended in ice-cold membrane buffer, homogenized by Dounce Homogenizer (Wheaton, Millville, NJ) and centrifuged for 20 min at 50,000 ***g***. The pellet was resuspended, homogenized, centrifuged again and the precipitate containing the plasma membranes was then suspended in the membrane buffer containing protease inhibitor (Sigma-Aldrich, St. Louis, MO) and stored at −80°C. Protein concentration was determined using a protein BCA assay kit (Pierce Biotechnology, Pittsburgh, PA). For homogeneous binding, cell membrane homogenates (10 µg protein per well) were incubated in membrane binding buffer (50 mM Tris-HCl, 10 mM NaCl, 0.1 mM EDTA, pH 7.4) with constant concentration of \[^3^H\]-CGS21680 (1 nM, PerkinElmer) and serial dilutions of unlabeled CGS21680 (0.26 nM to 100 µM) at room temperature for 3 hr. Nonspecific binding was determined in the presence of 100 µM CGS21680. Following incubation, the samples were filtered rapidly in vacuum through glass fiber filter plates (PerkinElmer). After soaking and rinsing four times with ice-cold PBS, the filters were dried and counted for radioactivity in a MicroBeta2 scintillation counter (PerkinElmer).

Surface expression of A~2A~Rs {#s4-11}
-----------------------------

HEK293 cells were seeded into six-well plate and incubated overnight. After transient transfection with WT or mutant plasmids for 24 hr, the cells were collected and blocked with 5% BSA in PBS at room temperature for 15 min and incubated with primary anti-Flag antibody (1:100, Sigma-Aldrich) at room temperature for 1 hr. The cells were then washed three times with PBS containing 1% BSA followed by 1 hr incubation with anti-rabbit Alexa-488-conjugated secondary antibody (1:1000, Cell Signaling Technology, Danvers, MA) at 4°C in the dark. After three washes, the cells were resuspended in 200 µl of PBS containing 1% BSA for detection in a NovoCyte flow cytometer (ACEA Biosciences, San Diego, CA) utilizing laser excitation and emission wavelengths of 488 nm and 519 nm, respectively. For each assay point, approximately 15,000 cellular events were collected, and the total fluorescence intensity of positive expression cell population was calculated.

Plasmid constructs of 5-HT~7~ receptor {#s4-12}
--------------------------------------

A plasmid encoding the 5-HT~7~ receptor was obtained from PRESTO-Tango Kit produced by Addgene (Watertown, MA). 5-HT~7~ coding sequence was amplified and ligated into the pRluc8-N1 vector to produce WT 5-HT~7~-Rluc8. Mutant 5-HT~7~-Rluc8 receptors were generated from this plasmid using the Quikchange mutagenesis kit (Agilent Technologies, Santa Clara, CA). A plasmid encoding the Nluc-EPAC-VV cAMP sensor was kindly provided by Kirill Martemyanov (The Scripps Research Institute, Jupiter, FL) and has been described previously. ([@bib117]) All plasmid constructs were verified by DNA sequencing.

Cell transfection {#s4-13}
-----------------

HEK293 cells cultured in 6-well plates were transiently transfected with the above plasmids (3.0 μg DNA) in growth medium using linear polyethyleneimine MAX (Polysciences, Warrington, PA) at an N/P ratio of 20 and used for experimentation 12--48 hr thereafter.

BRET cAMP and trafficking assays {#s4-14}
--------------------------------

HEK 293 cells transiently transfected with WT or mutant 5-HT~7~ receptor plasmids plus either the Nluc-EPAC-VV cAMP sensor (at a 15:1 ratio) or Venus-kras (at a 1:8 ratio) ([@bib175]) were incubated for 24 hr. After washing twice with PBS, they were transferred to opaque black 96-well plates. Steady-state BRET measurements were made using a Mithras LB940 photon-counting plate reader (Berthold Technologies GmbH, Bad Wildbad, Germany). Furimazine (NanoGlo; 1:1000, Promega) for cAMP measurement or coelenterazine h (5 µM; Nanolight, Pinetop, AZ) for trafficking assay was added followed by BRET signal detection and calculation at an emission intensity of 520--545 nm divided by that of 475--495 nm.

Data and materials availability {#s4-15}
-------------------------------

The open source code is available at GitHub ([@bib210]; copy archived at <https://github.com/elifesciences-publications/RRCS>). For availability of codes that were developed in-house, please contacts the corresponding authors. All data are available in the main text or the source data.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This manuscript reports the structural analysis of class A GPCR activation mechanism by developing a novel residue-residue contact score (RRCS) and comparing this score between the active and inactive class A GPCR structures. From this analysis, the authors propose an activation pathway from extracellular ligand binding to the intracellular coupling of signal transducers like G proteins. The proposed pathway involves four clusters (layers) of residues. This proposed activation mechanism is supported by the accompanying mutagenesis experiments.

**Decision letter after peer review:**

Thank you for submitting your article \"Universal activation mechanism of class A GPCRs\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Olga Boudker as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Essential revisions:

1\) There are more than 800 different GPCRs in human body, 45 structures were resolved in class A, and only 4 pairs of single static structures have been analyzed in details in this report. While the analysis aiming to reveal a shared GPCR activation mechanism is a meaningful attempt, it is premature to claim a \"universal\" activation mechanism. It would be surprising if the activation elements involved in Gs coupling and Gi coupling receptors are entirely conserved, given that the dramatic difference in the outward movement in the cytoplasmic end of TM6 and that the coupling of GPCRs with different intracellular transducers is subjected to different conformational changes. At best we can hope that the proposed mechanism provides a framework and a common language for future structural/mechanistic analysis of GPCRs, and different GPCRs (especially GPCRs of the A family) may to variously degrees and in different aspects resemble proposed mechanism. The entire manuscript, especially the title and the Abstract, needs revision in recognition of this understanding.

2\) Within this four detailed analyzed structure, RHO actually doesn\'t have agonist. It is not justified to include RHO as an example for analysis.

3\) Can the authors based on their proposal provide explanation of the basis for GPCR coupling to different G proteins using the RRCS analysis?

4\) The author always assumed that ligand binding is located above the highly conserved W6.48, but there are more and more new structures indicated that the ligand could actually diffuse as deep as below D2.50. This is represented by the structure of LTB4 receptor (Nat. Chem. Biol. 14: 262-269) as well as several others. The revision should discuss how a deeper ligand binding would affect their conclusion.

5\) Many non-orthosteric ligand binding site have been captured in crystal structures (Sci Rep. 2019; 9: 6180; Front Pharmacol. 2018; 9: 128). How does the proposed activation mechanism provides new insight to these non-orthosteric ligand bindings.

6\) The activation mechanism and G protein specificity have been extensively discussed previously (e.g. Nature Structural and Molecular Biology 25(2):185-194 (2018); Nature 545: 317-322 (2017); Nature 536: 484-487 (2016); Nature Chemical Biology 14: 1059-1066(2018); Chem. Rev.20171171139-155). A summary of these discussions should be provided in an expanded Introduction, and the proposed mechanism should be contextualized with respect to the current understanding. Related, the citation of 19 references in one stroke is highly unconventional; this should be revised with a more nuanced account of the current structural understanding of GPCRs.

7\) Certain aspects of the proposed model have already been reported, and the authors in the revision should make a special effort in making sure that these reports are properly cited.

8\) The description for the four layer elements in the activation pathway as \"modular\" is quite misleading. \"Modular\" means isolated and functionally independent, like classic DNA-binding domain and transcriptional activation domain in transcription factors, which can function separately and can be exchanged between transcriptional factors. In this paper, the modality of the four layers in GPCR activation has not been demonstrated. It is not clear whether layer elements can be exchanged between different receptors.

9\) Compared to the diverse residue types in the Class A GPCR activation pathways, residues involved in class B GPCR activation appeared to be much more conserved as presented in the recent PTH1R receptor. Discussing the difference and similarity of class A and class B GPCR activation will broaden the interests and impact of the paper.

10\) The authors introduced biological mutation experiment to support their ideas. It should be made clear that a positive result can only show the involvement of the mutated residue in GPCR activation, but cannot confirm a residue-residue interaction. With this in mind, the claims associated with the mutation data should be re-calibrated.

11\) The paper will be much strengthened if the mutagenesis experiments performed on A2aR are also performed for one of representative Gi coupled receptors. (Probably not the whole set of mutants but the representative CAM and CIM for a Gi coupled receptor.)

12\) To confirm the predicted residue-residue interactions, it would be highly desirable to use NMR to show correlated signal changes of the residue pairs.
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Author response

> Essential revisions:
>
> 1\) There are more than 800 different GPCRs in human body, 45 structures were resolved in class A, and only 4 pairs of single static structures have been analyzed in details in this report. While the analysis aiming to reveal a shared GPCR activation mechanism is a meaningful attempt, it is premature to claim a \"universal\" activation mechanism. It would be surprising if the activation elements involved in Gs coupling and Gi coupling receptors are entirely conserved, given that the dramatic difference in the outward movement in the cytoplasmic end of TM6 and that the coupling of GPCRs with different intracellular transducers is subjected to different conformational changes. At best we can hope that the proposed mechanism provides a framework and a common language for future structural/mechanistic analysis of GPCRs, and different GPCRs (especially GPCRs of the A family) may to variously degrees and in different aspects resemble proposed mechanism. The entire manuscript, especially the title and the Abstract, needs revision in recognition of this understanding.

We thank the reviewers for the comments. In the revised manuscript, we have reworked on the title, the Abstract and related contents to ensure the accuracy and clarity.

We discuss possible misunderstandings of our work below:

First, we analyzed 6 inactive *vs*. fully active pairs of structures in detail (listed in [Author response table 1](#resptable1){ref-type="table"}, inactive state is in orange) but not 4 pairs, as shown in Figure 2D, Figure 2---figure supplement 1, and Results paragraph two. These structures were picked based on their high quality. That is, they are all of high-resolution, no mutation or only one mutation in the transmembrane domain which is known not to affect receptor signaling. These 6 pairs were also selected for analysis by the previous research \[Venkatakrishnan, et al. Nature 536.7617 (2016): 484.\].

###### List of twelve structures of six receptors.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  GPCR     PDB code   Resolution (Å)                                   Ligand\                                              State          Mutation in the TM region
                                                                       G protein/G protein memetic                                         
  -------- ---------- ------------------------------------------------ ---------------------------------------------------- -------------- ---------------------------
  bRho     1GZM       2.7                                              11-cis-retinal (inverse agonist, covalently bound)   Inactive       No mutation

  3PQR     2.9        All-trans-retinal (agonist, covalently bound)\   Active                                               No mutation    
                      GαCT2 (G protein peptide)                                                                                            

  β~2~AR   2RH1       2.4                                              Carazolol (inverse agonist)                          Inactive       No mutation

  3SN6     3.2        BI-167107 (agonist)\                             Active                                               No mutation    
                      G~s~ (G protein)                                                                                                     

  M2R      3UON       3.0                                              3-quinuclidinyl-benzilate (antagonist)               Inactive       No mutation

  4MQS     3.5        Iperoxo (agonist)\                               Active                                               No mutation    
                      Nb9-8 (nanobody)                                                                                                     

  μOR      4DKL       2.8                                              β-funaltrexamine (antagonist)                        Inactive       No mutation

  5C1M     2.1        BU72 (agonist)\                                  Active                                               No mutation    
                      Nb39 (nanobody)                                                                                                      

  A~2A~R   3EML       2.6                                              ZM241385 (antagonist)                                Inactive       No mutation

  5G53     3.4        NECA (agonist)\                                  Active                                               No mutation    
                      Mini-G~s~ (engineered G protein)                                                                                     

  κOR      4DJH       2.9                                              JDTic (antagonist)                                   Inactive       I135L (3×29)

  6B73     3.1        MP1104 (agonist)\                                Active                                               I135L (3×29)   
                      Nb39 (nanobody)                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

More importantly, beyond the analysis on the six receptors, we performed a class-wide RRCS comparison between the 142 inactive and 27 active state class A GPCR structures to identify residue pairs showing statistically significant different RRCS scores (P\<0.001; two sample *t*-test) upon activation (Figure 2D, Figure 2---source data 2, Materials and methods). The combination of such an analysis and the across-class comparison could take the full advantage of tremendous successes of GPCR structural biology in the past decade, and only this exercise would give us the confidence to claim what we discovered are common to diverse class A GPCRs.

Second, the common activation pathway we discovered is a shared portion among G~s~, G~i~, and arrestin activation pathways of various receptors stimulated by various agonists. At the same time, receptors that do have their own receptor-, agonist-, and effector-specific pathways are not the focus of this study. Therefore, we totally agree that activation elements involved in G~s~ and G~i~ coupling are NOT entirely conserved (*i.e.*, biased signaling), and we had avoided to use this term in the manuscript.

> 2\) Within this four detailed analyzed structure, RHO actually doesn\'t have agonist. It is not justified to include RHO as an example for analysis.

We agree with the reviewers on the importance of structure selection to study receptor activation.

As listed in the [Author response table 1](#resptable1){ref-type="table"}, we used a high quality (2.9 Å resolution) structure (PDB: 3PQR) as the fully active state structure of Rho, which has all-trans-retinal (i.e., agonist) covalently bound.

In fact, we did investigate a low resolution (4.5 Å for the overall complex, in local resolution map, the receptor part has even a lower resolution) cryo-EM structure of the Rho-G~i~ complex (PDB: 6CMO), in which agonist is missing. It serves as a negative control for our analysis. We noticed that 6CMO has 8 pairs of residues that do not match the common activation pathway (*i.e.*, 8 outliers out of 34 residues pairs), and we attributed these mismatches to the rather low resolution of the structure and probably the missing of agonist. The positive control is a 3.1 Å crystal structure of the Rho-mini-G~o~ complex (PDB: 6FUF), for which no outliers were observed (Figure 4, Figure 4---figure supplement 1 and Figure 4---figure supplement 2). These results reflect that our RRCS approach is dependent on the high-quality structures.

> 3\) Can the authors based on their proposal provide explanation of the basis for GPCR coupling to different G proteins using the RRCS analysis?

This is a good question. After we developed the RRCS analysis, we have been trying to find possible applications for this method. In theory, this method could be used to analyze any system that have big or subtle but significant conformational changes. The limit is that it really relies on the accuracy of side chain conformations, thus high-resolution structures are the key.

We did apply the RRCS analysis to study G protein selectivity and failed to reach any meaningful conclusions. This may be caused by following reasons:

a\) Lack of high resolution GPCR-G protein complex structures. [Author response table 2](#resptable2){ref-type="table"} lists all available GPCR-G protein complexes to date (14 structures from 10 receptors). However, 6 of them have poor resolution (lines in gray) thus are not qualified for the RRCS analysis. For the other cryo-EM structures, carefully checking the local resolution for the GPCR-G protein interface but not directly use the overall resolution of the whole complex is need before doing any RRCS calculation, since in general, large G~β~ protein has the highest resolution in the complex. Hopefully, with more high-resolution complexes determined, RRCS analysis may help answer the question of G protein selectivity.

###### List of GPCR-G protein complex structures.

  Receptor   PDB code    Method    Resolution (Å)   Ligand + G protein/G protein memetic
  ---------- ----------- --------- ---------------- --------------------------------------
  A~2A~R     5G53        X-ray     3.4              NECA + Mini-G~s~
  A~2A~R     6GDG        cryo-EM   4.1              NECA + Mini-G~s~
  β~2~AR     3SN6        X-ray     3.2              BI-167107 + G~s~
  β~2~AR     6E67        X-ray     3.7              BI-167107 + Fused G~s~ C-terminal
  Rho        6CMO        cryo-EM   4.5              G~i~
  Rho        6FUF        X-ray     3.1              all-trans-retinal +Mini-G~o~
  μOR        6DDE/6DDF   cryo-EM   3.5              DAMGO + G~i~
  A~1A~R     6D9H        cryo-EM   3.6              Adenosine + G~i2~
  5-HT~1B~   6G79        cryo-EM   3.8              Donitriptan + G~o~
  CB1        6N4B        cryo-EM   3.0              MDMB-Fubinaca + G~i~
  NTSR1      6OSA        cryo-EM   3.0              JMV449 + G~i1~ (NC state)
  NTSR1      6OS9        cryo-EM   3.0              JMV449 + G~i1~ (C state)
  M2R        6OIK        cryo-EM   3.6              Iperoxo + LY2119620 +G~oA~
  M1R        6OIJ        cryo-EM   3.3              Iperoxo + G~11~

b\) It is known that G-protein activation is a complex process^1,\ 2^ which may have several states. Taking NTSR1--G~i1~ complexes for example, a canonical-state and a non-canonical state of G protein were determined showing different hNTSR1--G~i1~ interfaces. The complexity of this dynamic process also increases the difficulty of RRCS analysis.

c\) The G protein coupling region is much more diverse in sequence compared to intracellular half of the TM domain in which our common activation pathway locates. Thus, different receptors may recognize different positions of the G-protein through distinct residues, like multiple keys (receptors) opening the same lock (G protein) using non-identical cuts, as a previous study pointed out.^3^

> 4\) The author always assumed that ligand binding is located above the highly conserved W6.48, but there are more and more new structures indicated that the ligand could actually diffuse as deep as below D2.50. This is represented by the structure of LTB4 receptor (Nat. Chem. Biol. 14: 262-269) as well as several others. The revision should discuss how a deeper ligand binding would affect their conclusion.

We thank the reviewers for providing the valuable insights. We took this suggestion and added analysis for several crystal structures (PDB: 5X33, 6K1Q and 6BQH, [Author response table 3](#resptable3){ref-type="table"}), the ligand of which diffuses as deep as below D^2.50^. These ligands are all inverse agonists that touch/occupy the Na^+^ pocket. By taking the space of the Na^+^, they prevented the collapse of Na^+^ pocket, as well as blocking the rotation of W^6.48^, leading to lock the receptors to an inactive state.

###### List of three inverse agonist-bound structures.

  GPCR       PDB code   Ligand       Ligand type       Na^+^ mimic group in ligand   Occupying Na^+^ pocket
  ---------- ---------- ------------ ----------------- ----------------------------- ------------------------
  BLT1       5X33       BIIL260      Inverse agonist   Yes                           Yes
  ET~B~      6K1Q       IRL2500      Inverse agonist   No                            Yes
  5-HT~2C~   6BQH       Ritanserin   Inverse agonist   No                            No

These observations are consistent with our activation model and functional study of A~2A~R mutants. As shown in Figure 6, Figure 6---source data 1, Figure 6---source data 2 and Figure 6---figure supplement 1, three mutations of A~2A~R (L48^2x46^R, N280^7x45^R and N284^7x49^K) that form slat bridges with D^2.50^ and stabilize the inactive state were shown to abolish cAMP accumulation as expected.

Interestingly, for D^2.50^, only loss-of-function disease mutations (Figure 7B) or constitutively inactivating mutations (Figure 7C) were observed for 24 receptors, implying that D^2.50^ is indispensable for receptor activation. These finding are also supported by the NMR study of A~2A~R^4^, which demonstrated the role of D52^2.50^ as an allosteric link between the orthosteric drug binding site and the intracellular signaling surface^4^.

> 5\) Many non-orthosteric ligand binding site have been captured in crystal structures (Sci Rep. 2019; 9: 6180; Front Pharmacol. 2018; 9: 128). How does the proposed activation mechanism provides new insight to these non-orthosteric ligand bindings.

We thank the reviewers for raising this point. Exactly as the recommended literature revealed, allosteric modulation of GPCR provides a promising potential of pharmacological intervention, due to the diversity in location, mechanism, and selectivity of allosteric ligands.

A list of reported allosteric modulators among determined structures of class A GPCRs are listed in [Author response table 4](#resptable4){ref-type="table"}, with PAMs labeled in green.

###### List of allosteric modulators among determined structures of class A GPCRs.

  Location of binding site                             Receptor        Ligand                              Ligand type                     PDB code
  ---------------------------------------------------- --------------- ----------------------------------- ------------------------------- ----------
  Intracellular pocket                                 β~2~AR          CMPD-15PA                           Negative allosteric modulator   5X7D
  CCR9                                                 Vercirnon       Antagonist                          5LWE                            
  CCR2                                                 CCR2-RA-\[R\]   Antagonist                          5T1A                            
  Extra-helical binding site                           C5aR            NDT9513727                          Inverse agonist                 5O9H
  C5aR                                                 avacopan        Allosteric antagonist               6C1R                            
  C5aR                                                 NDT9513727      Allosteric antagonist               6C1Q                            
  β~2~AR                                               compound-6FA    Positive allosteric modulator       6N48                            
  P2Y1                                                 BPTU            antagonist                          4XNV                            
  GPR40                                                AP8             Full allosteric agonists (agoPAM)   5TZY                            
  GPR40                                                Compound 1      Full agonist                        5KW2                            
  PAR2                                                 AZ3451          Antagonist                          5NDZ                            
  Non-canonical binding pocket                         GPR40           TAK-875                             Ago-allosteric modulator        4PHU
  GPR40                                                MK-8666         Ago-allosteric modulator            5TZR                            
  PAR2                                                 AZ8838          antagonist                          5NDD                            
  Extracellular vestibule above the orthosteric site   M2              LY2119620                           Positive allosteric modulator   4MQT

As we can see, the locations of binding site are quite diverse for GPCR allosteric modulators, and so do the mechanisms as one can expect.

Here is our brief analysis of the possible mechanisms. A) Directly altering the common activation pathway. For example, for allosteric modulators bound to the intracellular pocket of their receptor (PDB: 5X7D, 5LWE and 5T1A), they exert antagonism by preventing G protein coupling. B) Having receptor-, ligand-, and effector-specific pathways. An example is compound-6FA (in PDB 6N58), which binds to the extrahelical surface of β~2~AR, but also directly interacts with G protein. C) A mixture of the above two mechanisms.

> 6\) The activation mechanism and G protein specificity have been extensively discussed previously (e.g. Nature Structural and Molecular Biology 25(2):185-194 (2018); Nature 545: 317-322 (2017); Nature 536: 484-487 (2016); Nature Chemical Biology 14: 1059-1066(2018); Chem. Rev.20171171139-155). A summary of these discussions should be provided in an expanded Introduction, and the proposed mechanism should be contextualized with respect to the current understanding. Related, the citation of 19 references in one stroke is highly unconventional; this should be revised with a more nuanced account of the current structural understanding of GPCRs.

We thank the reviewer for the comments. We significantly rewrote the Introduction part to reflect the previous understanding of GPCR activation. Many more references are cited now.

> 7\) Certain aspects of the proposed model have already been reported, and the authors in the revision should make a special effort in making sure that these reports are properly cited.

We thank the reviewer for this comment. We have greatly increased the citation and number of references to reflect previous findings on GPCR activation mechanism.

> 8\) The description for the four layer elements in the activation pathway as \"modular\" is quite misleading. \"Modular\" means isolated and functionally independent, like classic DNA-binding domain and transcriptional activation domain in transcription factors, which can function separately and can be exchanged between transcriptional factors. In this paper, the modality of the four layers in GPCR activation has not been demonstrated. It is not clear whether layer elements can be exchanged between different receptors.

We changed the word modular to modular nature, we meant each layer has different function and can be activated/inactivated in a rather independent manner, as shown in our mutagenesis study (Figure 6B).

Analyzing residue pairs in each layer of the common activation pathway for intermediate structures (*i.e.*, only agonist but not G protein bound structures) also supports the modular nature of the common activation pathway. As shown in [Author response image 1](#respfig1){ref-type="fig"}, β~2~AR (3PDS) only has layer 4 in the active state; 5-HT~2B~ (6DS0) has layers 2 and 3 partially activated, while leaving layers 1 and 4 not activated; A~2A~R (2YDV) and LPA~6~ (5XSZ) have layers 1-3 all partially activated, while leaving layer 4 untouched; and US28 (4XT1) has layers 2-4 in fully active state, while layer 1 is largely inactivated.

![Receptor activation process via intermediate structures (i.e., only agonist but not G protein bound structures) are in receptor- and ligand-specific manner, thereby highlighting the modular nature and complexity of the activation pathways.](elife-50279-resp-fig1){#respfig1}

> 9\) Compared to the diverse residue types in the Class A GPCR activation pathways, residues involved in class B GPCR activation appeared to be much more conserved as presented in the recent PTH1R receptor. Discussing the difference and similarity of class A and class B GPCR activation will broaden the interests and impact of the paper.

We thank the reviewers for this suggestion. Actually, the idea of applying RRCS on other allosteric systems including class B GPCRs is on our to-do-list. However, we have not done so due to the following reasons:

a\) Different from class A GPCRs, only one receptor (GLP-1R) has been determined with both inactive and fully active state structures, while other receptors only have either antagonist-bound inactive structures or G protein-bound active structures.

###### List of available class B GPCRs structures.

  Receptor   PDB code   Method    Resolution (Å)   Ligand + G protein/G protein memetic    States
  ---------- ---------- --------- ---------------- --------------------------------------- --------------
  CRF1R      4K5Y       X-ray     2.9              Antagonist CP-376395                    Inactive
  CRF1R      4Z9G       X-ray     3.2              Antagonist CP-376395                    Inactive
  CTR        6NIY       cryo-EM   3.3              Peptide ligand + G~s~                   Active
  CTR        5UZ7       cryo-EM   4.1              Peptide ligand + G~s~                   Active
  CGRP       6E3Y       cryo-EM   3.3              CGRP + G~s~                             Active
  GCGR       4L6R       X-ray     3.3              No ligand was seen                      Inactive
  GCGR       5EE7       X-ray     2.5              Antagonist MK-0893                      Inactive
  GCGR       5YQZ       X-ray     3.0              Partial agonist NNC1702                 Intermediate
  GCGR       5XEZ       X-ray     3.0              Negative allosteric modulator NNC0640   Inactive
  GCGR       5XF1       X-ray     3.2              Negative allosteric modulator NNC0640   Inactive
  GLP-1R     5VAI       cryo-EM   4.1              human GLP-1 + G~s~                      Active
  GLP-1R     6B3J       cryo-EM   3.3              Exendin-P5 + G~s~                       Active
  GLP-1R     5NX2       X-ray     3.7              Truncated peptide agonist               Intermediate
  GLP-1R     5VEW       X-ray     2.7              PF-06372222                             Inactive
  GLP-1R     5VEX       X-ray     3.0              NNC0640                                 Inactive
  PTH1R      6FJ3       X-ray     2.5              Peptide agonist ePTH                    Intermediate
  PTH1R      6NBH       cryo-EM   3.5              A long-acting PTH analog + G~s~         Active
  PTH1R      6NBI       cryo-EM   4.0              A long-acting PTH analog + G~s~         Active
  PTH1R      6NBF       cryo-EM   3.0              A long-acting PTH analog + G~s~         Active

b\) The active state structures of class B GPCRs are all EM structures, their resolutions are generally low compared to that of crystal structures. As mentioned before, the RRCS analysis highly relies on the quality of side chain conformations. More class B structures with resolution higher than 3.0 Å are needed.

c\) The primary results of RRCS on class B GPCRs revealed that RRCS could describe the well-known conformational changes including the HETX motif (Nature. 2017;546(7657):248-253^5^) very well ([Author response image 2](#respfig2){ref-type="fig"}).

![Calculated RRCS for the HETX motif in class B GPCRs.](elife-50279-resp-fig2){#respfig2}

The comparison of the activation mechanism between classes A and B GPCRs have been frequently discussed^6^. The most notable conformational change in class B GPCRs is the sharp kink and unwinding in the middle of TM6, as observed for GLP-1R^5^/CTR^7^/CGRP^8^/PTH1R^9^. Another notable difference is the signal initiation and transduction pathway: class A has PIF/CWxP/Na^+^ pocket/DRY/NPxxY motifs, while class B has totally different conserved motifs. Despite these differences, they both couple G protein in similar orientation, highlighting the converge of signal transduction in the cytoplasmic region.

> 10\) The authors introduced biological mutation experiment to support their ideas. It should be made clear that a positive result can only show the involvement of the mutated residue in GPCR activation, but cannot confirm a residue-residue interaction. With this in mind, the claims associated with the mutation data should be re-calibrated.

Thank the reviewer for raising this point. We were very careful when making mechanistic interpretations of the successfully predicted mutants, we always used the words "likely", "would", and "probably" to avoid any confirmation of residue-residue interactions, unless such interactions were reported by NMR studies.

> 11\) The paper will be much strengthened if the mutagenesis experiments performed on A2aR are also performed for one of representative Gi coupled receptors. (Probably not the whole set of mutants but the representative CAM and CIM for a Gi coupled receptor.)

Thank the reviewer for the suggestion. We expanded our mutagenesis studies to two additional receptors: G~s~-coupled 5-HT~7~ and G~i~-coupled 5-HT~1B~. The three mutations on the G~s~-coupled 5-HT~7~ were designed and validated by Dr. Nevin Lambert (who designed the mutations by directly following our designs on A~2A~R reported in the preprint of this manuscript. We did not interact with each other before this paper was submitted to the preprint server). The four mutations on the G~i~-coupled 5-HT~1B~ were validated by ourselves. All the mutations are remarkably consistent with what we discovered in A~2A~R. We added a new figure (Figure 6---figure supplement 2) to show the new mutagenesis data.

> 12\) To confirm the predicted residue-residue interactions, it would be highly desirable to use NMR to show correlated signal changes of the residue pairs.

This is an excellent suggestion. Exactly, NMR study could provide comprehensive and precise information on residue contacts changes upon receptor activation. Although we were unable to perform NMR study due to 2-month time limit and lack of expertise, we collected and analyzed published NMR data, which covered several regions in the common activation pathway, including residues at 5.57, 3.40, 5.58, 7.53, the Na^+^ pocket, TM6 and DRY motif. The following is a brief summary of our analysis.

Isogai et al. in the NMR study of turkey β~1~-adrenergic receptor (β~1~AR)^10^ demonstrated that chemical shifts of the labeled V226^5.57^ correlate linearly with ligand efficacies of the G protein pathway, thereby proving the involvement of residue 5.57 in receptor activation. The same NMR study also showed the participation of three residues (V129^3.40^, A227^5.58^, and L343^7.53^) in receptor activation through NMR response to ligand binding and point mutations (V129^3.40^I, A227^5.58^Y, and L343^7.53^Y) These results provide experimental evidence at high resolution of an extensive signal transduction network that connects the ligand binding site to the intracellular sides of TM5, TM6, and TM7.

Notably, 5.57, 3.40, 5.58 and 7.53 are nodes in our common activation pathway. Exactly as shown in Figure 5 and Figure 5---figure supplement 1, receptor activation involves the elimination of TM3-TM6 contacts, formation of TM3-TM7 and TM5-TM6 contacts, reflecting the outward movement of the cytoplasmic end of TM6 away from TM3, the inward movement of TM7 towards TM3 and the repacking of TM5 and TM6.

By using stable isotope NMR study for A~2A~ adenosine receptor (A~2A~R)^4^,Eddy et al. observed the interplay of the ''toggle switch'' W246^6.48^ with the allosteric center at D52^2.50^. The observation is modelled in Figures 3 and 5 of our manuscript.
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